Get the Stockscreener App
11.45
1.96%
0.22
Benitec Biopharma Inc stock is traded at $11.45, with a volume of 93,045.
It is up +1.96% in the last 24 hours and down -7.44% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$11.23
Open:
$11.39
24h Volume:
93,045
Relative Volume:
0.68
Market Cap:
$393.36M
Revenue:
$7,000
Net Income/Loss:
$-38.96M
P/E Ratio:
-12.32
EPS:
-0.9296
Net Cash Flow:
$-18.34M
1W Performance:
+6.81%
1M Performance:
-7.44%
6M Performance:
-12.02%
1Y Performance:
-13.19%
1-Day Range:
$11.14
$11.79
1-Week Range:
$10.72
$11.79
52-Week Range:
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
11.45 | 385.80M | 7,000 | -38.96M | -18.34M | -0.9296 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Benitec Biopharma’s SWOT analysis: gene therapy stock shows clinical promise - Investing.com Nigeria
BNTC Stock Price, Quote & Chart | BENITEC BIOPHARMA INC (NASDAQ:BNTC) - ChartMill
Citizens reiterates Benitec BioPharma stock rating on dose data By Investing.com - Investing.com Canada
Technical Reactions to BNTC Trends in Macro Strategies - Stock Traders Daily
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - Sahm
Benitec Biopharma Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Company Overview - Minichart
Benitec Biopharma Reports Q3 2026 Results: Strong BB-301 Clinical Progress for OPMD, $184.8M in Cash, Upcoming FDA Milestones - Minichart
Benitec Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Benitec Biopharma (BNTC) Fairly Valued After Q3 FY2026 Earnin - GuruFocus
Benitec Biopharma 3Q Loss/Shr 24c >BNTC - Moomoo
Benitec Biopharma Inc. Q3 2026: Revenue $0 Net loss $(11.9M), EPS $(0.24) — 10-Q Summary - TradingView
Benitec Biopharma reports Q3 FY2026 net loss $11.9M, cash $184.8M; advances BB-301 clinical program - TradingView
Benitec Biopharma (NASDAQ: BNTC) raises $100M to fund OPMD gene therapy BB-301 - Stock Titan
Benitec Biopharma Q3 net loss narrows as expenses fall - TradingView
BB-301 data, strong cash position shape Benitec (NASDAQ: BNTC) Q3 2026 - Stock Titan
BRIEF-Benitec Biopharma Q3 Operating Income USD -13.6 Million - TradingView
Evercore ISI initiates Benitec BioPharma stock coverage at outperform By Investing.com - Investing.com Australia
BNTC Initiates Coverage On Benitec Biopharma -- Rating Set to Ou - GuruFocus
Evercore ISI initiates Benitec BioPharma stock coverage at outperform - Investing.com UK
The scenario planning at Benitec (BNTC) | Q1 2026: Earnings Fall ShortSecondary Offering - Newser
The one metric that defines Benitec (BNTC) success (On the Radar) 2026-05-08Put Spread Alert - Newser
Trading the Move, Not the Narrative: (BNTC) Edition - Stock Traders Daily
Benitec Biopharma (BNTC) Expected to Announce Earnings on Wednesday - MarketBeat
Benitec presents OPMD gene therapy data at May conference - Investing.com UK
Benitec presents OPMD gene therapy data at May conference By Investing.com - Investing.com India
Rare swallowing disease study posts 24-month follow-up at gene therapy meeting - Stock Titan
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - ChartMill
Biotech founder behind a $14.6B sale joins Seaport board - Stock Titan
Biotech founder behind $14.6B sale joins Seaport board - Stock Titan
(BNTC) Volatility Zones as Tactical Triggers - Stock Traders Daily
Benitec (BNTC) Stock: Why Analysts Watch It (Breakout Watch) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Price-Driven Insight from (BNTC) for Rule-Based Strategy - Stock Traders Daily
Macro Review: How liquid is Benitec Biopharma Inc stock2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Quarterly Earnings: Does Benitec Biopharma Inc meet Warren Buffetts criteria2026 Earnings Surprises & Advanced Technical Signal Analysis - baoquankhu1.vn
Is Benitec Biopharma Inc part of any major index2026 Geopolitical Influence & High Return Trade Opportunity Guides - baoquankhu1.vn
Entry Recap: What is the Moat Score of Benitec Biopharma IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Is Benitec (BNTC) Stock Priced Correctly | Price at $10.93, Up 0.05%Social Trading Insights - Newser
(BNTC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Ideas Watch: How liquid is Benitec Biopharma Inc stockPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Sectors: Can Benitec Biopharma Inc maintain its current growth rate2026 Technicals & Weekly High Conviction Ideas - baoquankhu1.vn
Market Wrap: Is Benitec Biopharma Inc stock a buy or sellQuarterly Market Summary & AI Enhanced Trading Alerts - baoquankhu1.vn
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Shares Pass Below Fifty Day Moving Average – Here’s What Happened - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
(BNTC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Market Moves: Is Benitec Biopharma Inc forming a double bottom2026 Closing Moves & Verified Short-Term Plans - baoquankhu1.vn
BNTC SEC FilingsBenitec Biopharm 10-K, 10-Q, 8-K Forms - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) FY 2025 loss widens to $37.9M - Stock Titan
Benitec Biopharma | 10-K/A: Annual report (Amendment) - Moomoo
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):